Literature DB >> 3769058

Inhibition of ethinyloestradiol and tolbutamide metabolism by quinoline derivatives in vitro.

J H Riviere, D J Back.   

Abstract

The effects of the quinoline derivatives amodiaquine (AQ), chloroquine (CQ), mefloquine (MQ), primaquine (PQ), quinine (Q) and quinidine (QD) on in vitro hepatic metabolism has been studied using as substrates ethinyloestradiol (EE2) and tolbutamide (TOL). The 2-hydroxylation of EE2 and the hydroxylation of TOL were determined in the presence of variable concentrations of each compound. MQ, PQ, AQ and Q significantly inhibited EE2 metabolism at each of the concentrations studied (0.1, 0.2 and 0.5 mM) as shown by an increase in the percentage of unmetabolised EE2. QD significantly inhibited metabolism at 0.2 and 0.5 mM but CQ was without effect. In terms of recovery of 2-OHEE2, PQ was the most potent inhibitor. At an inhibitor concentration of 0.5 mM the order of potency was PQ greater than or equal to MQ greater than or equal to Q greater than or equal to QD greater than or equal to AQ greater than or equal to CQ. TOL hydroxylase activity in control microsomes was 1.52 +/- 0.33 nmol. min-1 X mg protein-1. The order of potency of the inhibitors (0.5 mM) was PQ greater than or equal to MQ greater than or equal to Q greater than or equal to QD greater than or equal to AQ greater than or equal to CQ. These data provide further evidence of the inhibitory potential of some of the quinoline derivatives. PQ, MQ, and to a lesser extent Q produce the most marked inhibitory effects. QD and AQ are of intermediate potency and CQ is essentially non-inhibitory.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3769058     DOI: 10.1016/s0009-2797(86)80075-8

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  8 in total

1.  Effect of oral contraceptive steroids on the clinical course of malaria infection and on the pharmacokinetics of mefloquine in Thai women.

Authors:  J Karbwang; S Looareesuwan; D J Back; S Migasana; D Bunnag; A M Breckenridge
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

2.  Single dose primaquine has no effect on paracetamol clearance.

Authors:  D J Back; J F Tjia
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Prophylactic phenobarbitone in young children with severe falciparum malaria: pharmacokinetics and clinical effects.

Authors:  P A Winstanley; C R Newton; G Pasvol; F J Kirkham; E Mberu; N Peshu; S A Ward; J B Were; D A Warrell; K Marsh
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

4.  Pharmacokinetics of mefloquine in combination with sulfadoxine-pyrimethamine and primaquine in male Thai patients with falciparum malaria.

Authors:  J Karbwang; D J Back; D Bunnag; A M Breckenridge
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

5.  In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines.

Authors:  D J Back; J F Tjia; J Karbwang; J Colbert
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

6.  Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide.

Authors:  D J Back; J Tjia; H Mönig; E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 7.  Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters.

Authors:  Slobodan Rendic; Frederick Peter Guengerich
Journal:  Curr Drug Metab       Date:  2020       Impact factor: 3.731

Review 8.  Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story.

Authors:  Amin Gasmi; Massimiliano Peana; Sadaf Noor; Roman Lysiuk; Alain Menzel; Asma Gasmi Benahmed; Geir Bjørklund
Journal:  Appl Microbiol Biotechnol       Date:  2021-01-30       Impact factor: 4.813

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.